You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDesflurane
Accession NumberDB01189  (APRD00907)
TypeSmall Molecule
GroupsApproved
DescriptionDesflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors.
Structure
Thumb
Synonyms
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
Desflurane
Desflurano
Desfluranum
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
Suprane
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SupraneLiquid240 mL/240mLRespiratory (inhalation)General Injectables & Vaccines, Inc2012-04-25Not applicableUs
SupraneLiquid240 mL/240mLRespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
SupraneLiquid100 %Respiratory (inhalation)Baxter Corporation1996-12-23Not applicableCanada
SupraneLiquid240 mL/240mLRespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
SupraneLiquid240 mL/240mLRespiratory (inhalation)Baxter Healthcare Corporation1992-09-18Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICRS35BZ94Q
CAS number57041-67-5
WeightAverage: 168.0378
Monoisotopic: 168.000983916
Chemical FormulaC3H2F6O
InChI KeyDPYMFVXJLLWWEU-UHFFFAOYSA-N
InChI
InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
IUPAC Name
2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
SMILES
FC(F)OC(F)C(F)(F)F
Pharmacology
IndicationFor use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults.
Structured Indications Not Available
PharmacodynamicsDesflurane is a general inhalation anesthetic. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionDesflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Desflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Desflurane also binds to and agonizes the GABA receptor, the large conductance Ca2+ activated potassium channel, the glycine receptors, and antagonizes the glutamate receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Glycine receptor subunit alpha-1Proteinyes
agonist
HumanP23415 details
Glutamate receptor 1Proteinyes
antagonist
HumanP42261 details
Potassium voltage-gated channel subfamily A member 1Proteinyes
inducer
HumanQ09470 details
Calcium-transporting ATPase type 2C member 1Proteinyes
inhibitor
HumanP98194 details
ATP synthase subunit delta, mitochondrialProteinunknown
other/unknown
HumanP30049 details
NADH-ubiquinone oxidoreductase chain 1Proteinunknown
unknown
HumanP03886 details
Related Articles
AbsorptionRapidly absorbed into the circulation via the lungs following inhalation.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Minimally biotransformed in the liver in humans (approximately 0.02% of the quantity absorbed).

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Desflurane is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with 7-Nitroindazole.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Desflurane.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Desflurane is combined with Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Desflurane is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Desflurane is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Desflurane.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desflurane.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Desflurane.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Desflurane is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Desflurane.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Desflurane.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Desflurane.Approved
AmiodaroneDesflurane may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Desflurane.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Desflurane is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Desflurane.Approved
AnagrelideDesflurane may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Desflurane.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Desflurane.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Desflurane.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Desflurane.Approved
Arsenic trioxideDesflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDesflurane may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Articaine.Approved
AsenapineDesflurane may increase the QTc-prolonging activities of Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Desflurane.Approved
Atracurium besylateDesflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Azaperone.Vet Approved
AzelastineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Desflurane is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Desflurane.Approved
AzithromycinDesflurane may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Desflurane is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Desflurane.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Desflurane.Approved
BedaquilineDesflurane may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Desflurane.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Desflurane.Approved
BenperidolThe risk or severity of adverse effects can be increased when Desflurane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desflurane.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Desflurane is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Desflurane.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Desflurane.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Desflurane.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Desflurane.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Desflurane.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
BromazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Desflurane.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Desflurane.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Desflurane.Approved, Investigational
BuprenorphineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Desflurane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Desflurane is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Desflurane.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Desflurane.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Desflurane.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desflurane.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Desflurane.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Desflurane is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Desflurane.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Desflurane.Approved, Investigational
CeritinibDesflurane may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Desflurane is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desflurane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Desflurane.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desflurane.Approved
ChloroquineDesflurane may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Desflurane.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorphenamine.Approved
ChlorpromazineDesflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Desflurane.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Desflurane.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Desflurane.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Desflurane.Approved, Vet Approved
CiprofloxacinDesflurane may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideDesflurane may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramDesflurane may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinDesflurane may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Desflurane.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Desflurane is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Desflurane is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Desflurane.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Desflurane is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane.Approved, Illicit
ClozapineDesflurane may increase the QTc-prolonging activities of Clozapine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Desflurane.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Desflurane.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Desflurane.Approved, Investigational
CrizotinibDesflurane may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Desflurane.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Desflurane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Desflurane is combined with deramciclane.Investigational
DesipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desflurane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Desflurane.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Desflurane is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desflurane.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Desflurane.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Desflurane.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Desflurane is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Desflurane.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Desflurane is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Desflurane.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desflurane.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desflurane.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Desflurane.Approved
DisopyramideDesflurane may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideDesflurane may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronDesflurane may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneDesflurane may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopamineDesflurane may increase the arrhythmogenic activities of Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Desflurane is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Desflurane.Approved
DoxepinThe risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Desflurane is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Illicit
DronedaroneDesflurane may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Desflurane is combined with Drotebanol.Experimental, Illicit
DuloxetineDesflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Desflurane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Desflurane is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Desflurane is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Desflurane is combined with Efonidipine.Approved
EliglustatDesflurane may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Desflurane.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Desflurane.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Desflurane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Desflurane is combined with Entacapone.Approved, Investigational
EphedraEphedra may increase the arrhythmogenic activities of Desflurane.Approved, Nutraceutical, Withdrawn
EphedrineEphedrine may increase the arrhythmogenic activities of Desflurane.Approved
EpinephrineDesflurane may increase the arrhythmogenic activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Desflurane.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Desflurane is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Desflurane.Approved
ErythromycinDesflurane may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramDesflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Desflurane.Approved
EstazolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Desflurane.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Desflurane.Approved
EthanolDesflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Desflurane.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Desflurane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Desflurane is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Desflurane is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Desflurane.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Desflurane is combined with Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Desflurane is combined with Fimasartan.Approved
FlecainideDesflurane may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Flunitrazepam.Approved, Illicit
FluoxetineDesflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolDesflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Desflurane is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desflurane.Approved, Investigational
FormoterolDesflurane may increase the arrhythmogenic activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Desflurane.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Desflurane is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Desflurane.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Desflurane is combined with gabapentin enacarbil.Approved
Gadobenic acidDesflurane may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Desflurane is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemifloxacinDesflurane may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Desflurane is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Desflurane is combined with Glutethimide.Approved, Illicit
GoserelinDesflurane may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronDesflurane may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Desflurane.Approved, Illicit, Withdrawn
HaloperidolDesflurane may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Desflurane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Desflurane is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Desflurane is combined with Hexobarbital.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Desflurane.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Desflurane.Approved, Vet Approved
HydrocodoneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Desflurane is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
IbutilideDesflurane may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneDesflurane may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Desflurane is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Desflurane is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Desflurane.Approved
IndoraminThe risk or severity of adverse effects can be increased when Desflurane is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Desflurane.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Desflurane is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Desflurane.Approved, Vet Approved
IsoprenalineDesflurane may increase the arrhythmogenic activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Desflurane.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Desflurane.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Desflurane.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Desflurane.Approved
KetamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketobemidone.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Desflurane.Approved
LacidipineThe risk or severity of adverse effects can be increased when Desflurane is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine.Approved, Investigational
LenvatinibDesflurane may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Desflurane is combined with Lercanidipine.Approved, Investigational
LeuprolideDesflurane may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Desflurane.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Desflurane.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Desflurane is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Levocetirizine.Approved
LevodopaDesflurane may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinDesflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Desflurane.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Desflurane is combined with Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Desflurane.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Desflurane.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Desflurane is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Desflurane is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Lofexidine.Approved, Investigational
LopinavirDesflurane may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Desflurane.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Desflurane.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Desflurane is combined with Lu AA21004.Investigational
LumefantrineDesflurane may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Desflurane.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Desflurane.Approved
MeclizineThe risk or severity of adverse effects can be increased when Desflurane is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Desflurane.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desflurane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Desflurane.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.Approved
MethadoneDesflurane may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Desflurane is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Desflurane.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Desflurane.Approved
MethotrimeprazineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Desflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Desflurane.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Desflurane.Approved
MethylphenidateMethylphenidate may increase the hypertensive activities of Desflurane.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Desflurane.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Desflurane.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Desflurane.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Desflurane.Approved, Investigational
MetyrosineDesflurane may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Desflurane.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Desflurane is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Desflurane.Approved
MirtazapineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumDesflurane may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Desflurane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Desflurane.Approved, Investigational
MoxifloxacinDesflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Desflurane.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Desflurane.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Desflurane.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Desflurane.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Desflurane.Approved
NicorandilNicorandil may increase the hypotensive activities of Desflurane.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Desflurane.Approved
NilotinibDesflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Desflurane is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Desflurane.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Desflurane.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Desflurane.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Desflurane.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineDesflurane may increase the arrhythmogenic activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Desflurane is combined with Obinutuzumab.Approved
OfloxacinDesflurane may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Desflurane.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Desflurane.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine.Approved
OndansetronDesflurane may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Desflurane is combined with Opium.Approved, Illicit
OrphenadrineDesflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desflurane.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Desflurane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Desflurane is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneDesflurane may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatDesflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Desflurane.Approved
ParaldehydeDesflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.Approved, Investigational
PazopanibDesflurane may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Desflurane.Approved, Investigational
PentamidineDesflurane may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Desflurane.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
PerazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Perazine.Investigational
PerflutrenDesflurane may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Desflurane.Approved
PerospironeThe risk or severity of adverse effects can be increased when Desflurane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Desflurane.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenelzine.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Desflurane.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Phenytoin.Approved, Vet Approved
PimozideDesflurane may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Desflurane.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Desflurane is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Desflurane is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.Approved
PramipexoleDesflurane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Desflurane.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Desflurane.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Desflurane.Approved
PrimaquineDesflurane may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Desflurane is combined with Primidone.Approved, Vet Approved
ProcainamideDesflurane may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Desflurane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.Approved, Vet Approved
PromazineDesflurane may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Promethazine.Approved
PropafenoneDesflurane may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Desflurane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Desflurane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Desflurane.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Desflurane is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Quazepam.Approved, Illicit
QuetiapineDesflurane may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Desflurane.Approved, Investigational
QuinidineDesflurane may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDesflurane may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Desflurane is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Desflurane.Approved
RapacuroniumDesflurane may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Desflurane is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Desflurane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Desflurane.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Desflurane.Approved
RisperidoneDesflurane may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Desflurane is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Romifidine.Vet Approved
RopiniroleDesflurane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Desflurane.Approved
RotigotineDesflurane may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Desflurane.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Desflurane is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Desflurane is combined with Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Desflurane is combined with Sage 547.Investigational
SaquinavirDesflurane may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Desflurane is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Desflurane is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
SotalolDesflurane may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Desflurane.Approved
StiripentolThe risk or severity of adverse effects can be increased when Desflurane is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Desflurane is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.Approved, Investigational
SulfisoxazoleDesflurane may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Desflurane.Approved
SuvorexantDesflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Desflurane is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Desflurane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Desflurane is combined with Tasimelteon.Approved
TelavancinDesflurane may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinDesflurane may increase the QTc-prolonging activities of Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Desflurane.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Desflurane.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Desflurane.Approved
TetrabenazineDesflurane may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Desflurane is combined with Tetrodotoxin.Investigational
ThalidomideDesflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desflurane.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Desflurane.Approved, Vet Approved
ThioridazineDesflurane may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Desflurane.Approved
TizanidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Desflurane is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Desflurane.Approved
ToremifeneDesflurane may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Desflurane.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Desflurane is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Desflurane.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desflurane.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Desflurane is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Desflurane.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Desflurane.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Desflurane.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Desflurane is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Desflurane is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Desflurane.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Desflurane.Approved, Investigational
VandetanibDesflurane may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibDesflurane may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Desflurane is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Desflurane.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Desflurane is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Desflurane is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Desflurane is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Desflurane is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Desflurane is combined with Zimelidine.Withdrawn
ZiprasidoneDesflurane may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Desflurane is combined with Zolazepam.Vet Approved
ZolpidemDesflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Desflurane is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Desflurane is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Desflurane is combined with Zotepine.Approved
ZuclopenthixolDesflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Leonid A. Rozov, Chialang Huang, Gerald G. Vernice, “Synthesis of desflurane.” U.S. Patent US5205914, issued June, 1991.

US5205914
General ReferencesNot Available
External Links
ATC CodesN01AB07
AHFS Codes
  • 28:04.00
PDB EntriesNot Available
FDA labelDownload (174 KB)
MSDSDownload (51.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9941
Caco-2 permeable+0.626
P-glycoprotein substrateNon-substrate0.883
P-glycoprotein inhibitor INon-inhibitor0.9415
P-glycoprotein inhibitor IINon-inhibitor0.9027
Renal organic cation transporterNon-inhibitor0.9311
CYP450 2C9 substrateNon-substrate0.8676
CYP450 2D6 substrateNon-substrate0.919
CYP450 3A4 substrateNon-substrate0.7556
CYP450 1A2 substrateNon-inhibitor0.6194
CYP450 2C9 inhibitorNon-inhibitor0.836
CYP450 2D6 inhibitorNon-inhibitor0.9466
CYP450 2C19 inhibitorNon-inhibitor0.707
CYP450 3A4 inhibitorNon-inhibitor0.9604
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8921
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.7045
BiodegradationNot ready biodegradable0.9566
Rat acute toxicity1.2690 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9724
hERG inhibition (predictor II)Non-inhibitor0.909
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidRespiratory (inhalation)100 %
LiquidRespiratory (inhalation)240 mL/240mL
Prices
Unit descriptionCostUnit
Suprane inhalation liquid0.76USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5617906 No1994-10-082014-10-08Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point23.5 °CNot Available
water solubilityNegligibleNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.54 mg/mLALOGPS
logP2.19ALOGPS
logP2.4ChemAxon
logS-1.7ALOGPS
pKa (Strongest Acidic)18.87ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity18.12 m3·mol-1ChemAxon
Polarizability7.89 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as halomethanes. These are organic compounds in which at least one of the four hydrogen atoms of methane (CH4) are replaced by halogen atoms.
KingdomOrganic compounds
Super ClassOrganohalogen compounds
ClassAlkyl halides
Sub ClassHalomethanes
Direct ParentHalomethanes
Alternative Parents
Substituents
  • Halomethane
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Grasshoff C, Antkowiak B: Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. Br J Anaesth. 2006 Nov;97(5):687-94. Epub 2006 Sep 13. [PubMed:16973644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dildy-Mayfield JE, Eger EI 2nd, Harris RA: Anesthetics produce subunit-selective actions on glutamate receptors. J Pharmacol Exp Ther. 1996 Mar;276(3):1058-65. [PubMed:8786535 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Matchett GA, Allard MW, Martin RD, Zhang JH: Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res. 2009 Mar;31(2):128-34. doi: 10.1179/174313209X393546. [PubMed:19298752 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Kosk-Kosicka D, Roszczynska G: Inhibition of plasma membrane Ca(2+)-ATPase activity by volatile anesthetics. Anesthesiology. 1993 Oct;79(4):774-80. [PubMed:8214757 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23